Compliance findings related to electronic records and signatures remain widespread among regulated pharmaceutical firms — and the findings typically don't arise from deliberate non-compliance. They arise from specific, recurring assumptions about what 21 CFR Part 11 actually requires.
The regulation itself — covering electronic records and electronic signatures in FDA-regulated environments — is not especially complex. The compliance failures that generate Form 483 observations and warning letters are typically not exotic. They are the product of specific assumptions that turn out not to hold up under inspection.
The most common Part 11 finding is inadequate audit trail functionality. The regulation requires a secure, computer-generated, time-stamped audit trail that records the date and time of operator entries and actions that create, modify, or delete electronic records. Per 21 CFR Part 11.10(e), the trail must include user identification, the original and new values of changed data, and must be available to the FDA for review and copying.
Many systems generate logs. Not all logs meet the specific requirements of 21 CFR Part 11. A system that records who logged in and when, but not what data was changed or what the original value was, does not provide a compliant audit trail.
Part 11 requires that computerized systems are validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records. FDA guidance on electronic records makes clear that validation is an ongoing obligation — not a one-time certification.
System updates, operating environment changes, and changes to how the system is used all have the potential to affect validated status. Regulated firms that validated their systems at implementation and haven't revisited validation documentation since are carrying a compliance risk that may only become visible during an inspection.
Part 11 addresses both electronic records (Subpart B) and electronic signatures (Subpart C), but they have distinct requirements. Per 21 CFR Part 11.100, electronic signatures must be unique to each individual, must be non-reusable and non-transferable, and must be linked to their respective records in a way that prevents them being used for falsification.
In practice, many organizations have robust electronic record controls but inadequate signature controls — shared passwords, signatures associated with a user role rather than an individual, or signature processes where the authentication step is separate from the record-linking step.
Part 11 applies to electronic records that are created, modified, maintained, archived, retrieved, or transmitted under any FDA records requirement. FDA guidance clarifies that this scope is broader than many regulated firms assume. Document comparison and proofreading tools used in the release of pharmaceutical labeling fall within this scope — if they generate or modify records that support product release decisions, those records are subject to Part 11 requirements.
↗ InformaIT's Content Compare includes Part 11-compliant audit trail functionality, validated for pharmaceutical GxP use. See what else to check for when evaluating a compliance-grade platform, or ask our team about our compliance documentation.